wen zhai

..............page:6-6

hui xun

..............page:7-7

Expert opinion on the clinical use of human insulin andanimal insulin
chen zuo zuo ;, dan zhong yan ;, zuo jing tao ;, ji li wei ;, li chun lin ;, li qi fu ;, li qiang ;, li zuo ;, li yi ming ;, mu yi ming ;, shi yong zuo ;, sun zi lin ;, xiao xin hua ;, yang wan hua ;, yu xue feng ;, zhao jia jun ;, zhao rong sheng ;, zhao zhi gang ;, zhu da long ;

..............page:8-10

Chinese experts consensus statement on metformin in theclinical practice
chen zuo zuo ;, dan zhong yan ;, guo li xin ;, hong tian pei ;, ji qiu he ;, ji li nong ;, ji li wei ;, li chun lin ;, li guang wei ;, li qi fu ;, li qiang ;, li yan bing ;, li zuo ;, li yi ming ;, liu chao ;, mu yi ming ;, ning guang ;, peng yong de ;, shi yong zuo ;, shi li xin ;, sun zi lin ;, tong nan wei ;, wang wei qing ;, wang you min ;, wu jiu hong ;, xiao xin hua ;, yang wan hua ;, yu xue feng ;, zhao jia jun ;, zhao rong sheng ;, zhao zhi gang ;, zhou zhi guang ;, zhu da long ;, zou da jin ;

..............page:11-22

New awareness to the relationship between obesity and type 2 diabetes
li zuo ;

..............page:23-26

Problem and challenge of traditionalanti-diabetic therapy in patients with type 2 diabetes
guo li xin ;

..............page:27-31

Current status and future of incretin-based therapies for type 2 diabetes
mu yi ming ;

..............page:32-37

Liraglutide protects pancreatic beta cellsand its early beneifts for type 2 diabetes
guo xiao zuo ;

..............page:38-43

The pharmacokinetics and pharmacodynamics characteristics of GLP-1 agonists
zhao zhi gang ;, zhu bin ;

..............page:43-47

Efficacy and safety of liraglutide treatment in patients with type 2 diabetes mellitus
zuo jing tao ;

..............page:48-52

Re-evaluation of cardiovascular safetyof incretin-based therapies
sun zi lin ;

..............page:53-58,68

Clinical value of GLP-1 receptoragonist in treatment of type 2 diabetic patients combined with obesity
ji qiu he ;

..............page:59-63

Common adverse reactions of GLP-1receptor agonist and their countermeasures
yu xue feng ;

..............page:64-68